Gabriele Siciliano, MD, PhD, University of Pisa, Pisa, Italy, shares his thoughts on exciting updates in the field of neuromuscular diseases. Prof. Siciliano feels that the development of novel agents is the most important aspect for the future of these diseases, and recent successes have paved the way for a promising development pathway. For example, apitegromab, a monoclonal antibody against myostatin, has recently demonstrated signs of early activity and has the potential to be the first muscle-directed therapy for patients with spinal muscular atrophy. This interview took place during the European Academy of Neurology 2021 congress.
Prof. Siciliano reports the following disclosures:
Academic research project financing: Sanofi, Biogen.
Advisory Boards: Lupin, Sparks, Novartis, CSL Behring.